Lamisil Dermgel (Terbinafine)

Terbinafine belongs to the allylamine class and inhibits the fungal enzyme squalene epoxidase. This blocks the conversion of squalene to ergosterol, leading to toxic squalene buildup and loss of ergosterol, an essential component of the fungal cell membrane, resulting in fungal cell death.

The appropriate amount and frequency of Lamisil Dermgel are determined by the prescribing healthcare professional based on the type and severity of the infection, patient age and other clinical factors. Patients should follow the specific instructions provided on the prescription label.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil Dermgel.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity and submit the request. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole creams, terbinafine has a different mechanism—squalene epoxidase inhibition—and often requires a shorter treatment duration for dermatophyte infections. It is generally well‑tolerated, but choice of therapy should be guided by infection type, resistance patterns and clinician preference.

Lamisil Dermgel should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

The gel is applied thinly to the affected skin area, usually once or twice daily as directed by a healthcare professional. The skin should be clean and dry before application, and hands should be washed after use to avoid inadvertent contact with eyes or mucous membranes.

Although rare, serious adverse reactions can include severe allergic skin reactions such as contact dermatitis, systemic hypersensitivity including anaphylaxis, and, in exceptional cases, liver toxicity. Patients should discontinue use and seek medical attention if they experience swelling, blistering, jaundice or other severe symptoms.

Individuals with known hypersensitivity to terbinafine, other allylamine antifungals or any component of the gel should avoid its use. It is also contraindicated on extensive broken skin or mucous membranes, and caution is advised for pregnant or breastfeeding women until safety is confirmed by a clinician.